Literature DB >> 15488553

PET: a revolution in medical imaging.

Abass Alavi1, Paras Lakhani, Ayse Mavi, Justin W Kung, Hongming Zhuang.   

Abstract

FDG-PET has had remarkable influence on the assessment of physiologic and pathologic states. The authors predict that FDG-PET imaging could soon become the most common procedure used by nuclear medicine laboratories and could remain so for an extended period of time. The power of molecular imaging lies in the vast potential for using biochemical and pharmacologic probes to extend applications arising from an understanding of cell biology to a large number of well-characterized pathologic states. Molecular imaging based upon tracer kinetics with positron-emitting radiopharmaceuticals could become the main source of information for the management of cancer patients. In that case, nuclear medicine procedures might become the most common imaging studies performed in the practice of medicine. This speculation is not farfetched when one realizes the enormous change that a single biologically important compound, FDG, has brought to the medical arena. The major challenge today is to attract the highly qualified individuals and to secure the resources needed to harness the opportunities in the specialty of molecular imaging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488553     DOI: 10.1016/j.rcl.2004.08.012

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  14 in total

1.  Apparent diffusion coefficient on magnetic resonance imaging (MRI) in bladder cancer: relations with recurrence/progression risk.

Authors:  Ken Kikuchi; Takeshi Shigihara; Yuko Hashimoto; Masayuki Miyajima; Nobuhiro Haga; Yoshiyuki Kojima; Fumio Shishido
Journal:  Fukushima J Med Sci       Date:  2017-07-05

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

4.  18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade.

Authors:  Song-Mee Cho; Yong Gyu Park; Joon Mo Lee; Jae Young Byun; Jae Mun Lee; Kyo-Young Lee; Gyeong-Sin Park; Hyeon-Sook Kim; Bae Young Lee; Kang-Hoon Lee; Kyung-Sup Song
Journal:  Eur Radiol       Date:  2006-06-20       Impact factor: 5.315

5.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

Review 6.  Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Rakesh Kumar; Sandip Basu; Drew Torigian; Vivek Anand; Hongming Zhuang; Abass Alavi
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

7.  The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.

Authors:  Michal E Schneider-Kolsky; Stewart Hart; Jane Fox; Peter Midolo; John Stuckey; Michael Hofman; Vinod Ganju
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466

8.  Assessment of global cardiac uptake of radiolabeled iron oxide nanoparticles in apolipoprotein-E-deficient mice: implications for imaging cardiovascular inflammation.

Authors:  André Luís Branco de Barros; Ann-Marie Chacko; John L Mikitsh; Ajlan Al Zaki; Ali Salavati; Babak Saboury; Andrew Tsourkas; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

9.  Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.

Authors:  Ayse Mavi; Sandip Basu; Tevfik F Cermik; Muammer Urhan; Mehdi Bathaii; Dhurairaj Thiruvenkatasamy; Mohamed Houseni; Simin Dadparvar; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-05-27       Impact factor: 3.488

10.  The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.

Authors:  Jian Zhang; Zhen Jia; Joseph Ragaz; Ying-Jian Zhang; Min Zhou; Yong-Ping Zhang; Gang Li; Bi-Yun Wang; Zhong-Hua Wang; Xi-Chun Hu
Journal:  BMC Cancer       Date:  2013-01-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.